The FDA has approved Eli Lilly's once-daily weight-loss pill, Foundayo, increasing competition in the obesity drug market dominated by Novo Nordisk. Despite this, Novo Nordisk's shares rose 2.6%, indicating investors had anticipated the challenge. Foundayo offers convenience without food or water restrictions but shows slightly less weight loss in trials compared to Novo Nordisk's oral and injectable treatments. This approval marks a shift towards oral obesity treatments, intensifying the rivalry between the two pharmaceutical giants.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
